Brief Title
Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma
Official Title
Phase II Study to Evaluate Efficacy and Safety of Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Patients With Nasopharyngeal Carcinoma
Brief Summary
This phase II trial is studying cisplatin or nedaplatin combine with IMRT to evaluate which one is better efficacy and security in nasopharyngeal carcinoma.
Study Phase
Phase 2
Study Type
Interventional
Primary Outcome
locoregionally control rate
Secondary Outcome
Survival
Condition
Nasopharyngeal Carcinoma
Intervention
Cisplatin
Study Arms / Comparison Groups
Cisplatin
Description: cisplatin combine with IMRT
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
20
Start Date
January 2011
Completion Date
December 2017
Primary Completion Date
December 2012
Eligibility Criteria
Inclusion Criteria: Age≥18,T1-2aN1-3;T2-4NxNPC,VEGFR+,++,KPS>70,Life expectancy≥6 months, No uncontrolled hypertension,cardiac failure,diabetes,lunacy Exclusion Criteria: Distant metastasis, recurrent disease
Gender
All
Ages
18 Years - 80 Years
Accepts Healthy Volunteers
No
Contacts
, 86(23)68757182, [email protected]
Location Countries
China
Location Countries
China
Administrative Informations
NCT ID
NCT01265147
Organization ID
Daping H 001
Study Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Study Sponsor
, ,
Verification Date
November 2010